Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PEPG

PepGen Inc

Sep 12 • 04:00PM ET

1.48

+0.13 9.63 %

Healthcare • Biotechnology • USA • NASD

Peers: SRPT RARE BMRN IONS ALNY ARCT QURE RNA WVE MGTX

| Held by: VTI VXF IBB IWC BTEC MSSM IBBQ BIB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.97	Insider Own	15.05%	Shs Outstand	32.80M	Perf Week	5.71%
Market Cap	48.54M	Forward P/E	-	EPS next Y	-1.75	Insider Trans	1.23%	Shs Float	27.86M	Perf Month	30.97%
Enterprise Value	-8.25M	PEG	-	EPS next Q	-0.63	Inst Own	74.78%	Short Float	4.07%	Perf Quarter	0.68%
Income	-96.92M	P/S	-	EPS this Y	8.70%	Inst Trans	-15.98%	Short Ratio	3.48	Perf Half Y	-34.22%
Sales	0.00M	P/B	0.68	EPS next Y	32.55%	ROA	-65.54%	Short Interest	1.13M	Perf YTD	-60.95%
Book/sh	2.17	P/C	0.65	EPS next 5Y	14.68%	ROE	-85.69%	52W High	10.06 -85.28%	Perf Year	-82.99%
Cash/sh	2.28	P/FCF	-	EPS past 3/5Y	-32.73% -116.35%	ROIC	-112.85%	52W Low	0.88 68.16%	Perf 3Y	-85.92%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	14.34% 9.82%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	10.04%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.74	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.65	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	4.74	EPS Q/Q	19.22%	SMA20	13.41%	Beta	1.19	Target Price	6.83
Payout	-	Debt/Eq	0.25	Sales Q/Q	-	SMA50	14.57%	Rel Volume	1.71	Prev Close	1.35
Employees	81	LT Debt/Eq	0.21	Earnings	Aug 07 BMO	SMA200	-26.29%	Avg Volume	325.39K	Price	1.48
IPO	May 06, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	17.28% -	Trades		Volume	557,566	Change	9.63%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-09-25	Initiated	Guggenheim	Buy	$6
Dec-16-24	Downgrade	BofA Securities	Neutral → Underperform	$3
Jul-31-24	Downgrade	BofA Securities	Buy → Neutral	$12
Dec-21-22	Initiated	H.C. Wainwright	Buy	$26

Aug-07-25 08:00AM	PepGen Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights (Business Wire) -13.14%
Aug-05-25 08:45AM	PepGen Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG (PR Newswire)
Aug-01-25 09:00AM	PepGen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before August 8, 2025 to Discuss Your Rights - PEPG (PR Newswire)
Jul-29-25 04:17PM	Investors in PepGen Inc. (PEPG): Protect Your Rights - Contact Levi & Korsinsky Before August 8, 2025 (Newsfile)
May-30-25 09:00AM	PepGen price target lowered to $1 from $3 at BofA (TipRanks) -12.57%
08:55AM	Loading…
08:55AM	PepGen to discontinue DMD programs after PGN-EDO51 did not achieve target (TipRanks)
06:36AM	Keros lays off nearly half its staff; Astellas buys into a China biotechs ADC (BioPharma Dive)
May-29-25 12:01AM	PepGen Inc. (PEPG) Halts DMD Program After Trial Miss; Shifts Focus to DM1 (Insider Monkey) +5.70%
May-28-25 04:05PM	PepGen to Focus on Development of Promising DM1 Program Following 10 mg/kg PGN-EDO51 Update (Business Wire) +7.48%
May-20-25 07:00AM	PepGen Appoints Kasra Kasraian, PhD, as Chief Technology Officer (Business Wire) +6.04%
May-08-25 08:00AM	PepGen Reports First Quarter 2025 Financial Results and Recent Corporate Highlights (Business Wire) +22.22%
Apr-02-25 04:05PM	PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +11.45% -14.04%
Mar-31-25 04:05PM	PepGen Announces Appointment of Two New Directors to its Board (Business Wire) -5.07% -6.76%
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha) -8.07%
Mar-26-25 10:17AM	The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs (SeekingAlpha)
04:05PM	Loading…
Mar-10-25 04:05PM	PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference (Business Wire) -9.54% +19.90%
Mar-05-25 06:32AM	PepGen pauses Phase II DMD trial to review safety data (Clinical Trials Arena) +15.57%
Mar-04-25 08:05AM	PepGen to Participate in Upcoming Investor Conferences (Business Wire) -18.86%
08:00AM	PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD (Business Wire)
Feb-25-25 07:38AM	PepGen reports positive initial data from Phase I DM1 therapy trial (Clinical Trials Arena) -25.33%
Feb-24-25 07:30AM	PepGen Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Corporate Highlights (Business Wire) +67.15%
07:00AM	PepGen Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1 (Business Wire)
Jan-31-25 07:21AM	PepGen price target lowered to $16 from $26 at H.C. Wainwright (TipRanks) -10.42%
Jan-29-25 04:05PM	PepGen Announces CONNECT Program Updates (Business Wire) -6.60% -21.74%
Jan-08-25 12:00PM	All You Need to Know About PepGen (PEPG) Rating Upgrade to Buy (Zacks)
Dec-16-24 08:00AM	PepGen Announces Clinical Hold in the U.S. on IND Application to Initiate CONNECT2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy (Business Wire)
Nov-21-24 04:05PM	PepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development (Business Wire)
Nov-07-24 08:00AM	PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights (Business Wire) -21.70%
Nov-04-24 08:00AM	PepGen to Participate in Upcoming Investor Conferences (Business Wire)
Oct-08-24 07:00AM	PepGen Announces Presentations at the 29th Annual Congress of the World Muscle Society (Business Wire)
04:30PM	Loading…
Sep-19-24 04:30PM	PepGen Announces Christopher Ashton, PhD, to Retire from its Board of Directors (Business Wire)
Aug-20-24 04:05PM	PepGen Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Executive Vice President, Research & Development (Business Wire)
08:00AM	PepGen Appoints Paul Streck, M.D., MBA, as Executive Vice President, Head of Research & Development (Business Wire)
Aug-08-24 08:00AM	PepGen Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights (Business Wire)
Aug-02-24 09:35AM	Down -39.63% in 4 Weeks, Here's Why You Should You Buy the Dip in PepGen (PEPG) (Zacks)
Jul-31-24 04:52AM	PepGen reports positive data from Phase II Duchenne muscular dystrophy trial (Clinical Trials Arena) -32.69%
Jul-30-24 04:02PM	PepGen Announces Positive Data from Low-Dose Cohort of PGN-EDO51 in Ongoing CONNECT1-EDO51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy (Business Wire)
Jul-17-24 08:50AM	Recent Price Trend in PepGen (PEPG) is Your Friend, Here's Why (Zacks)
Jul-02-24 08:00AM	PepGen Appoints Afsaneh Mohebbi, Ph.D., as SVP, Portfolio and Program Management and Dave Borah, CFA, as SVP, Investor Relations and Corporate Communications (Business Wire) -8.88%
Jun-11-24 07:00AM	PepGen Announces Executive Team Promotions (Business Wire)
May-15-24 01:20PM	PepGen Q1 Loss Narrows (MT Newswires)
May-14-24 10:55PM	PEPG Stock Earnings: PepGen Beats EPS for Q1 2024 (InvestorPlace) +5.19%
04:02PM	PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Apr-12-24 01:30PM	Hedge Fund and Insider Trading News: ExodusPoint Capital Management, Bridgewater Associates, Glenview Capital Management, PepGen Inc. (PEPG), HCI Group Inc (HCI), and More (Insider Monkey)
Mar-13-24 04:05PM	PepGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:00AM	PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Mar-12-24 09:55AM	Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? (Zacks)
Mar-11-24 12:00PM	PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-06-24 11:54PM	PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 (InvestorPlace) -7.34% -7.98%
04:01PM	PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Mar-04-24 07:00AM	PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Feb-29-24 03:02AM	14 Stocks With Heavy Insider Buying In 2024 (Insider Monkey) +14.68%
Feb-20-24 08:00AM	PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Feb-07-24 07:30AM	PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock (GlobeNewswire) +17.63%
Jan-17-24 07:00AM	Mary Beth DeLena Joins PepGen as General Counsel and Secretary (GlobeNewswire)
Jan-08-24 07:00AM	PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping (GlobeNewswire)
Dec-18-23 08:00AM	PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +6.03%
Nov-15-23 08:00AM	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors (GlobeNewswire)
Nov-08-23 08:00AM	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire) -10.40%
Oct-12-23 07:00AM	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +7.22%
Sep-27-23 04:16PM	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology (GlobeNewswire)
Sep-06-23 04:05PM	PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 (GlobeNewswire)
08:00AM	PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Companys Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences (GlobeNewswire)
Sep-01-23 08:00AM	PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-08-23 08:15AM	PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
Jun-13-23 04:05PM	PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1 (GlobeNewswire) +10.87% -7.99%
May-31-23 11:44AM	PepGen (PEPG) Down on Clinical Hold for DM1 Candidate (Zacks) -5.07%
May-30-23 04:05PM	PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate a Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
May-18-23 07:00AM	PepGen Announces Clearance by Health Canada of CTA for PGN-EDO51 to Begin the Phase 2 Clinical Trial, CONNECT1-EDO51, for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
May-11-23 07:00AM	PepGen Reports First Quarter 2023 Financial Results and Recent Corporate Developments (GlobeNewswire)
May-04-23 08:00AM	PepGen to Participate in the Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-17-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 American Academy of Neurology Annual Meeting (GlobeNewswire) +23.09%
Apr-13-23 04:05PM	PepGen to Participate in the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire) +6.07% -10.09%
Mar-27-23 02:25AM	PepGen Inc. (NASDAQ:PEPG) Q4 2022 Earnings Call Transcript (Insider Monkey) -16.15%
Mar-23-23 04:05PM	PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -9.77%
Mar-22-23 08:00AM	PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Mar-21-23 04:05PM	PepGen to Participate in the Stifel 2023 CNS Days Conference (GlobeNewswire)
Mar-16-23 08:00AM	PepGen to Host Fourth Quarter and Full Year 2022 Financial Results Call (GlobeNewswire) +6.99%
Mar-13-23 08:00AM	PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference (GlobeNewswire)
Feb-27-23 08:50AM	PepGen, Inc. (PEPG) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -6.02%
Feb-09-23 08:00AM	PepGen to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire) -5.07%
Jan-31-23 08:50AM	Here's Why Momentum in PepGen, Inc. (PEPG) Should Keep going (Zacks)
Jan-16-23 05:10AM	Companies Like PepGen (NASDAQ:PEPG) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-13-23 08:50AM	Here's What Could Help PepGen, Inc. (PEPG) Maintain Its Recent Price Strength (Zacks)
Dec-21-22 02:25PM	Why This PepGen Analyst Is Bullish On The Biotech Stock (Benzinga)
Dec-07-22 08:00AM	PepGen Announces IND-Enabling Preclinical Data Supporting Progression of PGN-EDODM1 into Clinical Studies (GlobeNewswire)
Dec-01-22 09:55AM	Wall Street Analysts See a 50% Upside in PepGen, Inc. (PEPG): Can the Stock Really Move This High? (Zacks) -6.42%
Nov-21-22 08:50AM	What Makes PepGen, Inc. (PEPG) a Good Fit for 'Trend Investing' (Zacks) +5.54%
Nov-15-22 09:55AM	Wall Street Analysts Predict a 68% Upside in PepGen, Inc. (PEPG): Here's What You Should Know (Zacks)
Nov-14-22 08:00AM	PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates (GlobeNewswire) +8.33%
Nov-10-22 08:00AM	PepGen Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) +12.92%
Nov-08-22 08:00AM	PepGen to Participate in the Stifel 2022 Healthcare Conference (GlobeNewswire)
Oct-13-22 01:00PM	PepGen Presents Data from its Duchenne Muscular Dystrophy Program at World Muscle Society Congress (GlobeNewswire)
Sep-28-22 01:59PM	PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst (Benzinga) +110.19%
09:25AM	PepGen Touts Encouraging Early-Stage Data From Duchenne Program (Benzinga)
06:00AM	PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy (GlobeNewswire)
Sep-22-22 08:00AM	PepGen Appoints Habib Dable to Board of Directors (GlobeNewswire)
Sep-04-22 07:17AM	3 IPO Stocks to Watch in September (TipRanks)
Aug-12-22 08:00AM	PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (GlobeNewswire) -6.70%
Aug-08-22 10:51AM	We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth (Simply Wall St.)

PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
STRECK PAUL	EVP, Head of R&D	May 30 '25	Buy	1.24	8,375	10,393	27,805	Jun 02 05:03 PM
McArthur James G	President and CEO	Apr 17 '25	Buy	1.35	10,000	13,550	113,913	Apr 22 07:01 AM
McArthur James G	President and CEO	Apr 08 '25	Buy	1.15	41,500	47,725	103,913	Apr 09 07:40 AM
DeLena Mary Beth	General Counsel	Feb 26 '25	Sale	1.68	1,432	2,406	1,568	Feb 26 08:24 PM
Donnelly Noel	Chief Financial Officer	Feb 26 '25	Sale	1.68	1,527	2,565	1,673	Feb 26 08:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PEPG

PepGen Inc

Upgrade your FINVIZ experience